Strategies and delivery systems for cell-based therapy in autoimmunity DOI Creative Commons
Matteo Puccetti, Claudio Costantini, Aurélie Schoubben

et al.

Frontiers in Drug Delivery, Journal Year: 2024, Volume and Issue: 4

Published: Aug. 8, 2024

This review article explores the potential of engineering antigen-presenting cells (APCs) for immunotherapy autoimmune diseases. It discusses various strategies modifying APCs to induce antigen-specific tolerance, thereby mitigating responses. The covers recent advancements in APC techniques, including genetic modification and nanoparticle-based approaches, evaluates their efficacy preclinical models clinical trials. Additionally, challenges future directions development APC-based immunotherapies autoimmunity – other forms cell-based are discussed. Along this direction, ( i ) describes APCs, modification, nanoparticle delivery systems, ex vivo manipulation techniques; ii selection target antigens design immunotherapies, iii reviews used evaluate safety engineered inducing tolerance.

Language: Английский

Cell therapies for immune-mediated disorders DOI Creative Commons
Natalia Krata, Bartosz Foroncewicz, Krzysztof Mucha

et al.

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: March 26, 2025

Immune-mediated disorders are a broad range of diseases, arising as consequence immune defects, exaggerated/misguided response or mixture both conditions. Their frequency is on rise in the developed societies and they pose significant challenge for diagnosis treatment. Traditional pharmacological, monoclonal antibody-based polyclonal antibody replacement-based therapies aiming at modulation responses give very often dissatisfactory results and/or burdened with unacceptable adverse effects. In recent years, new group treatment modalities has emerged, utilizing cells living drugs, especially use up-to-date genetic engineering. These modern cellular designed to offer high potential more targeted, safe, durable, personalized options. This work briefly reviews latest advances immune-mediated disorders, mainly those related exaggeration response, such hematopoietic stem (HSCs), mesenchymal stromal (MSCs), regulatory T (Tregs), chimeric antigen receptor (CAR) others. We highlight main features these options taming dysregulated system. Undoubtfully, near future can provide lasting remissions reduced burden improved quality life patients.

Language: Английский

Citations

0
CAR T-cell therapy in autoimmune diseases: where are we and where are we going? DOI
Marc Scherlinger, Gaétane Nocturne, Marko Radic

et al.

The Lancet Rheumatology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
Diverse potential of chimeric antigen receptor‐engineered cell therapy: Beyond cancer DOI Creative Commons

Lvying Wu,

Lingfeng Zhu, Jin Chen

et al.

Clinical and Translational Medicine, Journal Year: 2025, Volume and Issue: 15(4)

Published: April 1, 2025

Language: Английский

Citations

0
Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023 DOI Creative Commons
Wangshu Li, Jiuxiang Feng,

Jianan Peng

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: Oct. 16, 2024

Chimeric antigen receptor-natural killer (CAR-NK) cells represent a breakthrough in cancer immunotherapy, making this highly popular research area. However, comprehensive analyses of field using bibliometric methods are rare. To our knowledge, study has collected highest number publications (1,259) on CAR-NK therapy from January 1, 2004, to December 31, 2023, and utilized CiteSpace VOSviewer analyze regions, institutions, journals, authors, keywords forecast the latest trends research. The United States China, contributing over 60% publications, primary drivers field. Helmholtz Association Harvard University most active with appearing Frontiers Immunology. Winfried S. Wels is prolific author, while EL Liu frequently co-cited author. "Immunotherapy," "T-cells," "Cancer" extensively covered topics Our reveals current trends, identifies potential hotspots, visualizes references through methods, providing valuable guidance for future

Language: Английский

Citations

2
The B-cells paradigm in Systemic Sclerosis: an update on pathophysiology and B-cell targeted therapies DOI Creative Commons
Cristina Scaletti, Sara Pratesi, Silvia Bellando-Randone

et al.

Clinical & Experimental Immunology, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 5, 2024

Abstract Systemic sclerosis (SSc) is considered a rare autoimmune disease in which there are alterations of both the innate and adaptive immune response resulting production autoantibodies. Abnormalities system compromise normal function blood vessels leading to vasculopathy manifested by Raynaud’s phenomenon, an early sign SSc . As consequence this reactive picture, can evolve tissue fibrosis. Several SSc-specific autoantibodies currently known associated with specific clinical manifestations prognosis. Although pathogenetic role these still unclear, their B cells plasma suggests importance development SSc. This review narratively examines B-cell dysfunctions pathogenesis discusses B-cell-targeted therapies used or potentially useful for management end-organ complications.

Language: Английский

Citations

2
Strategies and delivery systems for cell-based therapy in autoimmunity DOI Creative Commons
Matteo Puccetti, Claudio Costantini, Aurélie Schoubben

et al.

Frontiers in Drug Delivery, Journal Year: 2024, Volume and Issue: 4

Published: Aug. 8, 2024

This review article explores the potential of engineering antigen-presenting cells (APCs) for immunotherapy autoimmune diseases. It discusses various strategies modifying APCs to induce antigen-specific tolerance, thereby mitigating responses. The covers recent advancements in APC techniques, including genetic modification and nanoparticle-based approaches, evaluates their efficacy preclinical models clinical trials. Additionally, challenges future directions development APC-based immunotherapies autoimmunity – other forms cell-based are discussed. Along this direction, ( i ) describes APCs, modification, nanoparticle delivery systems, ex vivo manipulation techniques; ii selection target antigens design immunotherapies, iii reviews used evaluate safety engineered inducing tolerance.

Language: Английский

Citations

1